3rd Generation Packaging System Mix

Cat. No.

LV053

Unit

200 µl

Price

$355.00

Cat. No.

LV053

Name

3rd Generation Packaging System Mix

Unit

200 µl

Description

For the production of lentiviral particles, three components are generally required: 1) a lentiviral vector containing your inserts of interest, 2) one or two packaging vectors which contain all necessary viral structure proteins, 3) an envelope vector expressing Vesicular Stomatitis Virus (VSV) glycoprotein (G).

The 3rd generation packaging system offers maximal biosafety as the lentiviral Rev gene is supplied as an independent vector from other structure genes, further eliminating the possibility of reverse recombination of vectors into replication competent viral particles.

The 3rd generation lentiviral packaging mix will only support lentiviral expression vectors with a chimeric 5' LTR in which the HIV promoter is replaced with CMV or RSV, thus making it TAT-independent. The 3rd generation lentiviral vectors will not support the production of 2nd generation lentiviral particle productions. All of the lentiviral vectors marketed by ABM are TAT-independent.

Packaging Mix Components:

Additional Information

Shelf Life: Up to 1 year (when stored at -20°C in a frost-free freezer).

Storage Condition

-20°C or below (shipped at ambient temperature)

Note

NOT FOR RESALE without prior written consent of ABM. This product is distributed for laboratory research only.

Promotions

Bundle up, save more! These cost-saving bundles combine our best-selling Lentivirus Packaging Mix with reagents for transfection, virus titration, and transduction!

Material Citation

If use of this material results in a scientific publication, please cite the material in the following manner: Applied Biological Materials Inc, Cat. No. LV053

Datasheet

LV053 Datasheet

Search CoA here

Supporting Protocol

Other

	What is the usual survival rate of cells after initial infection? I transduced two types of cells and after 72 hour incubation, one cell line had 50% dead, the other had just about 85-90% dead. Any pointers?
	Each cell line is different; like two different people, one with a drug sensitivity and one without, there is no means of comparison between cell lines. There are variations in the membrane transporters for the selection marker as well as cell transduction efficiency, so each cell line must be treated differently and their optimal killing curves must be determined independently.

	Are there any safety issues to consider if using lentiviral vectors in the same laboratory where replication competent adenovirus work is being carried out? For instance, can elements of one become incorporated into another under certain conditions (e.g . giving rise to a replication competent retrovirus)?
	If the adenovirus does not code for the viral packaging genes of the lentivirus, there is no safety issue. To remove all safety concerns, we recommend not to clone the viral packaging genes of the lentivirus into the adenoviral genome.

	Which cell line is better for high-titer lentivirus production - 293T or 293FT cells?
	Our 293T was clonally selected to be fast-growing and transfected easily and thus also supports high-level expression of viral proteins. We routinely use them to produce very high titer (10^10) lentivirus. Both cell lines are capable for proficient lentivirus production.

	What is the ratio of the three packaging plasmids when packaging via 293 cells?
	The three plasmids are present in equal molarity and in equal ratio.

	Is it possible to grow the plasmids up when they are mixed?
	No, it is not possible to grow up the plasmids from the product.

	Which system should I use to package my TAT dependent vector?
	TAT dependent vectors will need to be packaged using a 2nd generation system (abm Cat LV003). 3rd generation packaging systems (abm Cat. LV053) will not be compatible with this type of vector.

	What is the concentration of your packaging mixes?
	0.5ug/ul

	What is the titer for viruses made by Cat# LV053 with 293T cells?
	For both our 2nd or 3rd generation packaging mixes, the crude viral supernatant (i.e. not concentrated nor purified) titer will be around 10^6IU/ml.

	Is RRE present?
	Yes, it is present after Pol in pLenti-P3A.

Chan, MM et al. "Proteome profile and lentiviral transduction of cultured honey bee (Apis mellifera L.) cells" Insect Mol Biol 19(5):653-8 (2010). DOI: 10.1111/j.1365-2583.2010.01022.x. PubMed: 20546039.
Ordelheide, AM et al. "Nor-1, a novel incretin-responsive regulator of insulin genes and insulin secretion" Mol Metab 2(3):243-55 (2013). DOI: 10.1016/j.molmet.2013.06.003. PubMed: 24044104.
Kim, D et al. "Peroxisomal dysfunction is associated with up-regulation of apoptotic cell death via miR-223 induction in knee osteoarthritis patients with type 2 diabetes mellitus" Bone 64C:124-131 (2014). DOI: 10.1016/j.bone.2014.04.001. PubMed: 24727161.
Kim, D et al. " Two non-coding RNAs, MicroRNA-101 and HOTTIP contribute cartilage integrity by epigenetic and homeotic regulation of integrin-α1" Cell. Signal. 25:2878 - 87 (2013). DOI: 10.1016/j.cellsig.2013.08.034. PubMed: 24018042. Application: Viral Packaging.
George, R et al. "A SHORT INTERFERING RNA MOLECULAR BEACON FOR THE ATTENUATION OF MYCOBACTERIAL INFECTION" American Journal of Biochemistry and Biotechnology 10:40-49 (2014). DOI: 10.3844/ajbbsp.2014.40.49. Application: Viral Packaging.
Song, J et al. "A long non-coding RNA, GAS5, plays a critical role in the regulation of miR-21 during osteoarthritis" Journal of Orthopaedic Research 32(12):1628-1635 (2014). DOI: 10.1002/jor.22718. PubMed: 25196583.
Song, J et al. "MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis" BBA Clin : (2014). DOI: 10.1016/j.bbacli.2014.11.009. PubMed: 26673737.
Morgan, S et al. "β-Agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent" J Biol Chem 289(33):23065-23075 (2014). DOI: 10.1074/jbc.M114.557652. PubMed: 24973219.
Kim, D et al. "Peroxisomal dysfunction is associated with up-regulation of apoptotic cell death via miR-223 induction in knee osteoarthritis patients with type 2 diabetes mellitus" Bone 64:124-131 (2014). DOI: 10.1016/j.bone.2014.04.001. PubMed: 24727161. Application: Viral Packaging.
Song, J et al. "miR-370 and miR-373 regulate the pathogenesis of osteoarthritis by modulating one-carbon metabolism via SHMT-2 and MECP-2, respectively" Aging Cell 5:826-837 (2015). DOI: 10.1111/acel.12363. PubMed: 26103880.
Song, J et al. "A long non-coding RNA, GAS5, plays a critical role in the regulation of miR-21 during osteoarthritis" J Orthop Res 32(12):1628-1635 (2014). DOI: 10.1002/jor.22718. PubMed: 25196583. Application: Gene Delivery, Lentivirus.
Song, J et al. "MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis" BBA Clin. :79-89 (2015). DOI: 10.1016/j.bbacli.2014.11.009.
Song, J et al. "PBMC and exosome-derived Hotair is a critical regulator and potent marker for rheumatoid arthritis" Clin Exp Med. 1:121-126 (2015). DOI: 10.1007/s10238-013-0271-4. PubMed: 24722995.
Kang, Y et al. "PCGEM1 stimulates proliferation of osteoarthritic synoviocytes by acting as a sponge for miR-770" J Orthop Res. : (2015). DOI: 10.1002/jor.23046.
Rong, H et al. ""Notch signaling suppresses regulatory T cell function in murine experimental autoimmune uveitis "" Immunology 149.4:447-459 (2016). DOI: 10.1111/imm.12663.
Wang, J et al. "Radiofrequency hyperthermia-enhanced herpes simplex virus-thymidine kinase/ganciclovir direct intratumoral gene therapy of hepatocellular carcinoma" American Journal of Cancer Research 6.9:2054–2063 (2016). DOI: 10.1080/02656736.2016.1229045. Application: Animal infection.
Kang, et al. "PCGEM1 stimulates proliferation of osteoarthritic synoviocytes by acting as a sponge for miR-770" Journal of Orthopaedic Research 34.3:412 (2016). DOI: 10.1002/jor.23046. Application: Lentiviral infection.
Jin, G., Li, Y., Zhang, F., Li, P., Zhao, L., Zhou, Y., ... & Yang, X. "Epithelial ovarian cancer: feasibility of image-guided intratumoral radiofrequency hyperthermia-enhanced direct gene therapy" American journal of cancer research 9(2):378 (2019).
Omura, H., Liu, F., Shimakami, T., Murai, K., Shirasaki, T., Kitabayashi, J., Funaki, M., Nishikawa, T., Nakai, R., Sumiyadorj, A., Hayashi, T., Yamashita, T., Honda, M., Kaneko, S. "Establishment and Characterization of a New Cell Line Permissive for Hepatitis C Virus Infection" Scientific Reports 9:7943 (2019). DOI: 10.1038/s41598-019-44257-5.
Takemoto, K., Kobatake, K., Miura, K., Fukushima, T., Babasaki, T., Miyamoto, S., Sekino, Y., Kitano, H., Goto, K., Ikeda, K., Hieda, K., Hayashi, T., Hinata, N., & Kaminuma, O. (2022). <scp>BACH1</scp> promotes clear cell renal cell carcinoma progression by upregulating oxidative stress‐related tumorigenicity. Cancer Science, 114(2), 436–448. https://doi.org/10.1111/cas.15607
Hung, C.-N., Chen, M., DeArmond, D. T., Chiu, C. H.-L., Limboy, C. A., Tan, X., Kusi, M., Chou, C.-W., Lin, L.-L., Zhang, Z., Wang, C.-M., Chen, C.-L., Mitsuya, K., Osmulski, P. A., Gaczynska, M. E., Kirma, N. B., Vadlamudi, R. K., Gibbons, D. L., Warner, S., … Taverna, J. A. (2023). AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages. Cell Reports, 42(9), 113067. https://doi.org/10.1016/j.celrep.2023.113067
Liu, P., Nadeef, S., Serag, M. F., Paytuví-Gallart, A., Abadi, M., Della Valle, F., Radío, S., Roda, X., Dilmé Capó, J., Adroub, S., Hosny El Said, N., Fallatah, B., Celii, M., Messa, G. M., Wang, M., Li, M., Tognini, P., Aguilar-Arnal, L., Habuchi, S., … Orlando, V. (2024). PRC2-EZH1 contributes to circadian gene expression by orchestrating chromatin states and RNA polymerase II complex stability. The EMBO Journal, 43(23), 6052–6075. https://doi.org/10.1038/s44318-024-00267-2
Maurin, M., Ranjouri, M., Megino-Luque, C., Newberg, J. Y., Du, D., Martin, K., Miner, R. E., Prater, M. S., Wee, D. K. B., Centeno, B., Pruett-Miller, S. M., Stewart, P., Fleming, J. B., Yu, X., Bravo-Cordero, J. J., Guccione, E., Black, M. A., & Mann, K. M. (2023). RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-44126-w
Ryplida, B., Kim, D., Jin, E.-J., & Park, S. Y. (2023). Coenzyme a-responsive hydrogel sensor for wireless monitoring and treatment of osteoarthritis. Chemical Engineering Journal, 476, 146479. https://doi.org/10.1016/j.cej.2023.146479
Yang, L., Pham, K., Xi, Y., Wu, Q., Liu, D., Robertson, K., & Liu, C. (2024). Exploring Glypican-3 Targeted CAR-NK Treatment and Potential Therapy Resistance in Hepatocellular Carcinoma. https://doi.org/10.22541/au.170664301.11370201/v1
Shirasaki, T., González-López, O., McKnight, K. L., Xie, L., Shiota, T., Chen, X., Feng, H., & Lemon, S. M. (2022). Nonlytic Quasi-Enveloped Hepatovirus Release Is Facilitated by pX Protein Interaction with the E3 Ubiquitin Ligase ITCH. Journal of Virology, 96(21). https://doi.org/10.1128/jvi.01195-22
Lai, T. H., Ahmed, M., Hwang, J. S., Zada, S., Pham, T. M., Elashkar, O., & Kim, D. R. (2021). Transcriptional Repression of Raf Kinase Inhibitory Protein Gene by Metadherin during Cancer Progression. International Journal of Molecular Sciences, 22(6), 3052–3052. https://doi.org/10.3390/ijms22063052
Chan, C.-H., Chiou, L.-W., Lee, T.-Y., Liu, Y.-R., Hsieh, T.-H., Yang, C.-Y., & Jeng, Y.-M. (2022). PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib. British Journal of Cancer, 128(1), 148–159. https://doi.org/10.1038/s41416-022-02032-w
Chou, C.-W., Hung, C.-N., Chiu, C. H.-L., Tan, X., Chen, M., Chen, C.-C., Saeed, M., Hsu, C.-W., Liss, M. A., Wang, C.-M., Lai, Z., Alvarez, N., Osmulski, P. A., Gaczynska, M. E., Lin, L.-L., Ortega, V., Kirma, N. B., Xu, K., Liu, Z., … Huang, T. H.-M. (2023). Phagocytosis-initiated tumor hybrid cells acquire a c-Myc-mediated quasi-polarization state for immunoevasion and distant dissemination. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-42303-5
Suzuki, H., Nagase, S., Saito, C., Takatsuka, A., Nagata, M., Honda, K., Kaneda, Y., Nishiya, Y., Honda, T., Ishizaka, T., Nakamura, K., Nakada, T., Abe, Y., & Agatsuma, T. (2024). Data from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models. https://doi.org/10.1158/1535-7163.c.7104454.v1